A Melbourne-based biotech backed by billionaire Andrew Forrest says it has successfully tested a monthly injection to help children with peanut allergies safely build up a tolerance to the lethal condition.
Aravax, funded by Forrest’s venture capital fund Tenmile and Brandon Capital, said the treatment uses peptides to retrain the immune system to tolerate peanut. Almost three per cent of children in Australia have a peanut allergy that is potentially lethal and difficult to treat.
Gift articles to anyone you choose each month when you subscribe.
